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ABSTRACT Evidence-based medicine is often described as the ‘template’ for evidence-
based policymaking. EBM has evolved over the last 70 years, and now tends to be metho-
dologically pluralistic, operates through speciﬁc structures to promote EBM, and is inclusive
of a wide range of stakeholders. These strategies allow EBM practitioners to effectively draw
on useful evidence, be transparent, and be inclusive; essentially, to share power. We identify
three lessons EBP could learn from EBM. Firstly, to be more transparent about the processes
and structures used to ﬁnd and use evidence. Secondly, to consider how to balance evidence
and other interests, and how to assemble the evidence jigsaw. Finally–and this is a lesson for
EBM too–that understanding power is vital, and how it shapes how knowledge is produced and
used. We suggest that advocates of evidence use, and commentators, should focus on
thinking about how the type of problem faced by decision-makers should inﬂuence what
evidence is produced, sought, and used.
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Introduction
This paper summarises how commentators and advocateshave thought about evidence use in medicine and policyover the previous decades. We draw on existing literature
to outline the debates about the main challenges to the evidence-
use movements, and the strategies used by advocates to address
these challenges. At times, the EBM and EBP movements
have developed in parallel. Here, we compare the two move-
ments, and identify lessons for each (and their critics) to learn.
Finally, we summarise the main answered, and unanswered
questions for researchers and practitioners of evidence-based
decision-making.
Advocates of evidence-based policy (EBP) justiﬁably use
evidence-based medicine (EBM) as a template for their activities.
Health care is getting more effective, and the proliferation of
clinical guidelines to cover more and more of the changing face of
clinical practice indicates the success of this institutional
approach (Montori, 2008). However, advocates of EBP sometimes
use an idealised template of EBM, which indicates that all policy/
practice decisions should be predominantly based on research
evidence–even that only some forms of research are ‘valid’
enough to support decision-making–the randomised controlled
trial (RCT) and systematic review. It is immediately obvious that
this strict version simply wouldn’t work for EBP, as it dismisses
too much useful information, and does not take account of
people’s experiences and values. Critical commentators of EBP
observe that ‘evidence-use’ is hard to diagnose and/or categorise
(Parkhurst, 2017b; Smith 2013a), that focusing on evidence-use
risks ignoring most of the machinery of decision-making (Oliver
et al., 2014), and that what needs addressing by researchers and
practitioners of evidence-based decision-making, is the ‘human
factor’; power, actors, and context (Freudenberg and Tsui, 2013;
Oliver et al., 2012; Wesselink et al., 2014).
This strict version is, however, a caricature. These days, most
sensible people agree that there are good reasons for research
evidence not overruling clinical experience by default: for
example, the incompleteness of the evidence base or that clinical
and lay experience should be recognised as vital components in
the decision-making process, alongside a range of research types
(Head, 2010). Instead, EBM is often presented as a practice where
clinical decision-making is seen as a site of negotiation between
different stakeholders, which include the (researcher-derived)
evidence base, the clinician, the patient, and providers of care and
services generally. Drawing on this perspective, we present three
key lessons from these debates for practitioners of EBM and EBP.
First, that although the tools and practices developed by EBM
(privileging RCTs and systematic reviews over practitioner dis-
cretion) and EBP (led by demands for evidence from political
decision-makers) are different, there are opportunities for greater
transparency about decision-making processes in policy. Second,
we argue that EBM has developed ways to try and balance
researcher, practitioner and public knowledge, without compro-
mising methodological rigour or privileging some perspectives
over others. Learning to assemble the evidence jigsaw is a com-
plex process which goes beyond methodological pluralism, but
requires research evidence to be applied in varying settings and
balanced with other interests, potentially extending to the use of
deliberative processes to develop consensus between different
stakeholder values and priorities. Third, we argue that, whatever
the epistemological stance of the practitioner, it is vital to
understand the role of power in evidence-informed decision-
making; that examining who exerts power and how, is funda-
mental to understanding how the practice of evidence-use occurs
in both medicine and policy. Simply stating that power needs to
be shared, or that deliberative processes should be used to reach
consensus, does not helps us to describe, understand, or address
underlying power imbalances in knowledge production, govern-
ance, or use.
The evolution of EBM: a roadmap for EBP?
EBM has evolved signiﬁcantly since its inception, with Cochrane’s
answer to the injunctive of ‘do no harm’ (Cochrane, 1972). The
opening salvo in the EBM movement was a call to use high-
quality research evidence to select only effective interventions,
ideally the RCT, which can provide evidence on effectiveness
(whether an intervention has the desired outcome) and efﬁciency
(whether this effect translates outside the research setting) of an
intervention (Sibbald and Roland, 1998; Victora et al., 2004).
RCTs reduce the role of chance in determining the outcome of
experiments, and thus allow causal statements about the utility of
interventions to be made with relative conﬁdence. The 1990s saw
the enshrinement of the RCT as the ‘gold standard’ form of
evidence for EBM, often being portrayed as sitting atop the
‘hierarchy of evidence’ (Petticrew and Roberts, 2003) an heuristic
to determine the credibility of research evidence in developing
clinical guidelines and recommendations (see, e.g., GRADE
(Ansari et al., 2009) and National institute for Health and Clinical
Excellence (NICE) processes (NICE, 2004). Since these early days,
limitations to the use of the RCT have been increasingly high-
lighted (Cartwright, 2007; Oliver et al., 2010; Victora et al., 2004),
and in the last decade, the cultural hegemony of the RCT has
come under attack as its ethical, pragmatic, political, and meth-
odological limitations ––have become more apparent (Pearce
et al., 2015).
To many advocates of EBP, including some politicians, it
seemed self-evident that policy should be based on the best
available evidence. Coming to prominence in the UK under the
Blair Government, EBP assumed that with enough ‘sound evi-
dence’ it was possible to move beyond the vagaries of party
politics to reach “a ﬁrm high ground in the policy swamp”
(Parsons, 2002, p 45). Drawing on the EBM template, the RCT
was promoted as an optimal way to test and evaluate policy, with
the UK civil service becoming increasingly supportive (Ettelt
et al., 2015; Haynes et al., 2012; Oakley, 2000; Pearce and Raman,
2014; Pearce et al., 2015). In the US particularly, there is both a
culture of policy innovation and experimentation, and, through
the existence of the federal states, the means to conduct large-
scale social experiments (Baron, 2009; Kalil, 2014).
However, it is now widely accepted in EBM that a range of
evidence types should be used by clinicians and patients when
making decisions, and that decision-making processes should be
transparent and inclusive. This started in response to a need to
cover more of the realities of patient experience and clinical
practice (Greenhalgh and Hurwitz, 1999; Hammersley, 2007). We
also now recognise the role of values and interpretation in
understanding evidence, such that one piece of evidence may
have multiple meanings (Pearce and Raman, 2014; Smith, 2014).
While these moves were signiﬁcant in medicine, methodolo-
gical pluralism has always been more acceptable in policy (Ingold
and Monaghan, n.d.; Murphy and Fafard, 2012). Policy meanings
affect the presentation, acceptance and framing of evidence and
are vital to identifying levers for action (Grundmann and Stehr,
2012; Pearce et al., 2017).
Policymakers have always had to consider multiple framings of
policy problems (Gold, 2009; Russell et al., 2008). In medicine,
problem identiﬁcation and diagnosis is relatively uncontested,
whereas getting agreement on the nature of policy
problems–let alone causes or solutions - is challenging (Cairney,
2012; Liverani et al., 2013; Weiss, 1979, 1991). The ‘hierarchy of
evidence’ has less currency in an environment where
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policymakers must balance economic, ﬁnancial, ideological and
other perspectives on single issues (Lin, 2003). This is both a
strength, in that policy has access to a diverse jigsaw of evidence,
and a weakness in that the quality and reliability of such evidence
is contested. It is not always clear what evidence is used, how it is
identiﬁed, or who gets a voice in its production and interpretation
(Dobrow et al., 2004; Oliver and de Vocht, 2017; Oliver and
Lorenc, 2014).
Indeed, the narrow technocratic version of EBP which sub-
scribes to the primacy of the RCT is now mainly used as a straw
man (evidenced in, e.g., Freiberg and Carson, 2010; Marmot,
2004; Pawson, 2002). A signiﬁcant amount of research and
commentary has been conducted on multiple fronts; to guide
policymakers to use research evidence more effectively in the
UK (Cabinet Ofﬁce, 1999; Campbell et al., 2007), Australia
(Banks, 2009) and the USA (Laura and John Arnold Foundation,
2016); to investigate factors hindering evidence use (Innvaer et al.,
2002; Oliver et al., 2013; Orton et al., 2011) and to develope
interventions aiming to ‘upskill’ policymakers or help them to
access the ‘best’ available evidence more efﬁciently (see, e.g.,
(Armstrong et al., 2013; Dobbins et al., 2009; Ward, 2017), or for
a recent synthesis (Boaz et al., 2011)). Yet, there are still useful
lessons that EBP could learn from EBM, and vice versa.
Accepting that both EBM and EBP are more nuanced in
practice, than in caricature, what lessons can they learn from one
another?
Lesson one: be more transparent. EBP advocates could learn
from EBP about how to develop clear and transparent processes
and structures to inform decision-making. Institutions such as
NICE provide epistemic governance and accountability regarding
the creation and utilisation of knowledge–through, for example
the clinical guidelines process, wherein groups of clinical and lay
individuals assess systematic reviews of the literature and, toge-
ther, produce sets of recommendations for clinical practice.
Elsewhere, health research funders have supported collaborations
between clinical and academic staff (such as the CLAHRCs, in the
UK, and ZonMy in the Netherlands), in which research topics are
co-developed, and/or ﬁndings implemented and evaluated.1
Focusing more on research, the James Lind Alliance2 is an
example of the development and application of an explicit process
to co-produce research agendas on health topics, drawing on the
input of patients, carers, and practitioners to rank proposed
research questions on a particular topic (Beresford, 2000; Jona-
than Boote et al., 2010; Boote et al., 2002; Oliver, 2006; Stewart
et al., 2011). However, there are few evaluations of whether these
structures change either research or population-level outcomes.
Within policymaking, there has been similar investment in
organisations institutionalise or formalise the process of identify-
ing and codifying of evidence, and the translation of such
evidence into policy recommendations. Again in the UK, the
Blair/Brown Governments endorsed the “what works” principle,
and funded What Works Centres, NICE and the Education
Endowment Fund (Parsons, 2001). More recently, a variety of
non-governmental bodies have entered the evidence ‘mix’, such as
the Behavioural Insights Team, NESTA and IPPR in the UK, and
Laura and John Arnold Foundation and Brookings in the US.
While these are often well-resourced and sometimes inﬂuential,
little is yet known about how, and how well, the knowledge
produced by these new initiatives is taken up, or whether it leads
to changes in population or patient outcomes (Head, 2017).
While many have recognised that the policy process is
nuanced and negotiated rather than linear (Ettelt et al., 2015;
Pearce et al., 2015; Sarewitz, 2009; Sarewitz et al., 2004), there
remains strong support for the view that research evidence ought
to inform more of policymaking (see, e.g., Armstrong et al., 2013;
Dobbins et al., 2009; Ward, 2017). Yet, nothing in EBP compares
to the transparency with which EBM ﬁnds and incorporates
evidence into its decision-making processes.
Lesson two: balance inputs to assemble the evidence jigsaw.
Next, it is important for decision-makers to think critically about
what evidence is needed in the context of a particular decision;
what research evidence, whose voices, which interests and values
need to be heard. EBP advocates could usefully learn from EBM
about the importance of context and individual variation
in situations, the expertise of decision-makers, and technical
advice on how to interpret research evidence for speciﬁc situa-
tions which may not be identical to research settings. As we have
shown, EBP can learn from EBM in recognising that a ‘horses for
courses’ sensibility can help match knowledge requirements with
appropriate methodological approaches (Parkhurst and Abey-
singhe, 2016; Petticrew and Roberts, 2003). This may should, in
theory, also include public interests occasions, or the deployment
of other methods on other occasions. EBM has come to mean the
integration of individual clinical expertise with external clinical
evidence (Sackett et al., 1996), with patient experience and per-
spectives (Stefanie Ettelt and Mays, 2011; Greenhalgh and Hur-
witz, 1999; Trisha Greenhalgh, 2016; Green and Thorogood,
2009; Pope and Mays, 1993), and the standardisation of the
profession through formal structures (Greenhalgh et al., 2014).
One formative EBM text frames the inclusive nature of modern
EBM as a way to ‘help’ the experienced medic, rather than
overrule them with science (Sackett et al., 1996).
In addition, EBM has exerted considerable effects to include a
greater range of stakeholders in both the production of new
evidence (i.e., the research process), and the use of this evidence.
Lay members are part of groups which develop clinical practice
recommendations after deliberating on the evidence, and Patient
and Public Involvement (PPI) boards in health and social care
aim to move beyond research participation to actively involve
patients and public as advisers in the research process, or possibly
co-researchers (National Institute of Health Research, 2014). In
short, PPI shifts research from something done ‘to’, ‘for’ or
‘about’ the public to an activity done ‘with’ or ‘by’ the public
(Boote et al., 2010)
EBP can also be seen as a site of negotiation, between the
historic challenges of balancing multiple perspectives, and more
recent efforts to increase public participation and introduce
greater rigour into evidence production. While policymaking is
sometimes framed as an elite activity (Haas, 1992; Rhodes and
Marsh, 1992; Scott, 2001), democratic processes should, in theory,
also include public interests, either through representation by
elected politicians or by more direct participation. Advocates of
greater civil inclusion in policy research and processes argue that
there is an instrumental and moral value to including lay people
(Epstein et al., 2014; Jasanoff, 2003; Wynne, 1992). Others
interpret this as a repudiation of expertise (Kuntz, 2012, 2016),
even leading one political scientist to call for democracy to be
replaced by epistocracy, ‘rule by the knowledgeable’(Brennan,
2016). In general, however, greater public participation and ‘open
policymaking’ is becoming the norm (Burall et al., 2013; Burgess,
2014; Pallett, 2015). In practice, this trend faces the same problem
as EBM: how to properly consider ‘lay’ perspectives that may
differ radically from evidence provided by well-established
sources. Finding ways to include civil society and other interests
in democratic processes is challenging, time consuming, and
arguably at odds with the smooth running of government.
Similarly, in an era of ‘big politics’ many members of the public
are feeling increasingly disempowered and therefore disinclined
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to participate in ofﬁcial inputs to policy (Bang, 2009; Flinders and
Dommett, 2013; McCluskey et al., 2004). Despite the growth in
knowledge production institutions like the What Works Centres,
the structures set up to support EBP, and in particular the
strategies employed by these structures, are much less explicitly
delineated than the cognate structures for EBM
Lesson three: understand how power shapes knowledge pro-
duction and use. Some have begun to use policy studies to
explore the importance and dynamics of power, inclusivity and
advocacy (e.g., Cairney, 2017; Liverani et al., 2013; Pearce, 2014;
Wesselink et al., 2014; Head, 2008). Acknowledging the impor-
tance of power, however, has not yet been taken on board by
practitioners when developing strategies to support evidence
informed decision-making (Fafard, 2015; Head, 2010; Murphy
and Fafard, 2012; Parkhurst, 2017b; Smith, 2013a).
As indicated above, practitioners of EBM recognise that there
are power imbalances between researchers and the public; and
between practitioners and patients. However, merely recognising
such power differentials does not tell us how to negotiate them
appropriately, particularly in terms of how to assign legitimacy to
the evidence provided by each stakeholder (researcher; profes-
sional; patient), or about the circumstances under which it is
appropriate to rely on the experience of one stakeholder over
another. While EBM provides a forum for shared discussion and
sense-making, the navigation of social hierarchies is uncharted
territory.
The response to this dilemma has been to produce new and
inclusive structures for the production of knowledge (through co-
productive approaches) and for its implementation and use
(through inclusion of stakeholders in guideline development
groups). It is often assumed, that “appropriate” evidence, ﬁltered
and nuanced in the right way by the right actors (often termed
“deliberative approaches” or “public deliberation” by scholars in
the ﬁeld), consensus is possible (for example, see Conklin et al.,
2008; Duke, 2016; Smith, 2013b).
Yet, although new structures can formalise processes of
decision-making, they do not necessarily lead to inclusion of a
diverse (or appropriate) set of expert voices. Recruitment to
stakeholder/advisory groups or decision-making committees is
rarely a transparent process, and often by invitation. Moreover,
treating participants in a deliberative process as ‘representatives’
of an (unclear) population is unfair, yet recognising their
individual histories and agendas is almost impossible to square
with the ideal of value-free, methodologically rigorous decision-
making. Finally, consensus is seen as a desirable goal, which
indicates that power has been balanced and evidence appro-
priately considered and used (Horst and Irwin, 2010). We dispute
all these assumptions, and suggest that consensus may not always
be possible (Hendriks, 2009) and that the effects of consensus-
seeking can vary depending on political systems and cultures
(Dryzek and Tucker, 2008). Indeed, terms such as ‘evidence
uptake’ or ‘improvement of evidence use’ mask the complexities
and politics of knowledge transfer (Parkhurst, 2017a)3
Increased sensitivity to competing values and policy frames in
society can help reconnect policymaking to its inescapably
political context, an approach that stands in opposition to the
technocratic orientation of EBP (Hawkins and Parkhurst, 2015;
Parsons, 2002). As well as producing and utilising appropriate
knowledge, maximising the use of evidence ultimately boils down
to the importance of human judgement. Just as medical
professionals have to judge the applicability of the available
evidence to a patient, so policy experts must act as mediators
between the knowledge base and policy problem (Grundmann,
2017; Ingold and Varone, 2012; Turnhout et al., 2013). EBM can
therefore offer an active research agenda, but provides few lessons
to EBP on reconciling different perspectives.
How can we better understand how, and why power matters?
We suggest that means looking at the entire system of ‘epistemic
governance’ to better understand how knowledge is produced and
used by decision-makers (Pearce and Raman, 2014). For instance,
how issues are framed, and how politicised they become, affects
what knowledge will be considered legitimate and credible, which
research is commissioned and used, and who becomes author-
itative and powerful (Hartley et al., 2017, Brown 2015). Both EBM
and EBP impose political agendas by impelling practitioners to
make choices based on the available research. For example, health
policy research focuses on reducing morbidity and mortality,
rather than, for instance, problematizing and understanding the
roles of social categories (Liverani et al., 2013; Parkhurst and
Abeysinghe, 2016). If we see evidence production as driven by
ease rather than public need, this raises important question about
how research agendas are set; about how the knowledge pro-
duction system operates; and of whether researchers should be
open about their political values or the envisaged political end-
game of their research (Pielke Jr., 2007).
This implies that future approaches to evidence use must go
beyond calls for more structures or greater methodological
pluralism. Instead we need better heuristics to determine what
kinds of evidence are needed and for what purposes, considering
the kinds of question being asked, the actions which may be taken
as a result, and the politicisation of the problem. One potential
way to navigate these complex issues is to consider some types of
question being asked, and how this might affect the type of evi-
dence being used. Examples may include:
1. What is the nature of this problem?
2. What have others done?
3. How do I win this argument?
4. This is new, what do I do?
The substantive topic in question will affect which types of
evidence are required to answer, a dynamic unrecognised within
many hierarchies of evidence and evidence appraisal systems
(such as GRADE). For example, a doctor may observe a new
response to a drug, or a new combination of symptoms (Q type
3). This may be highly political (e.g., huge increase in presenta-
tion of gender dysphoria in a small community) or uncon-
troversial (such as a new side effect of a drug). The question “what
do I do?” will need very different consideration for both these
situations. Similarly, it is possible to imagine situations in both
medicine and policy where there is a desire to ‘win an argu-
ment’, but marshalling the appropriate evidence will depend on
the actors involved, the politicisation of the topic in question, and
so forth.
Politicisation of the topic in question is an under-explored
facet of the ‘evidence-based’ paradigm, and one which gets to the
heart of the technocratic/democratic tensions in the ideology (van
Eeten, 1999). This is at least partly by design. Presenting the EB
process as value-free, methodologically driven, and uncon-
troversial allows decision-makers to de-politicise potentially risky
debates, and disarms potential opponents by making it harder to
challenge (Boswell, 2017). One reason for EBP coming to such
prominence in the New Labour years may be that Blair was more
fearful of a predominantly right-wing press than previous gov-
ernments, helping to drive the depoliticisation of knowledge
production and utilisation (Parsons, 2002). While EBM’s new
structures focused on co-producing evidence through new
methods, EBP’s new structures looked to tame existing metho-
dological pluralism as a means of legitimising decision-making,
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through producing and legitimising evidence in a way which
reduced the scope for political attack and was amenable to the
trend for ‘joined-up government’ (Davies, 2009).
Conclusions
We have summarised major trends in the literature on EBP and
EBM and identiﬁed three key lessons for practitioners and
commentators in both. Yet, implicit in the research and solutions
(brokers, collaborative structures, shared power and decision-
making) of both EBP and EBM is that a mix of appropriate
evidence, experts, processes and structures will lead to improved
decision-making. In fact, we do not know whether collaborative
or co-productive research structures lead to more effective deci-
sion-making, or even better research. EBP and EBM are clearly
different in terms of the machinery of decision-making, the types
and number of actors involved, the structural constraints, the
range of decisions to be taken and the diversity of evidence
requiring consideration. Yet, constructing EBP as similar to EBM
is understandable; it is a cipher connoting a recognisable process,
and comes with a ready-made set of polemical devices and
methodological tools. While both EBM and EBP share a desire to
use evidence more effectively in decision-making, unpacking the
history, decision-making processes and responses to some of the
methodological and political challenges encountered by each, we
have demonstrated that there are also fundamental differences.
Using a typology of questions as a lens to consider which kinds of
evidence may be useful, shows us that politicisation of a pol-
icy issue, alongside methodological concerns, inﬂuences what is
considered credible and useful evidence. Advocates concerned
with increasing evidence uptake, in either ﬁeld, should draw on
ideas about politicisation and legitimacy when devising strategies
to increase research use.
As our discussion on politicisation shows, whenever a decision
is taken, a problem must be framed in order to bound any dis-
cussion. This process of framing is an expression of power, and
informs the selection of evidence types which will be used in any
discussion (Boswell, 2014; van Hulst and Yanow, 2014). Yet, rare
indeed is the expression of power which does not lead to the
prioritisation of some interests over others. Thus, we contend that
conﬂict is an inevitable part of both policy and clinical practice,
due to the values and perceptions of the actors involved in each.
Collaborative decision-sharing structures are, while a nice idea,
still subject to the same group dynamics, personal biases and
relationships as any other human interaction (Hendriks, 2009).
Neither have we solved the problem of how far researchers should
go to inﬂuence debates about policy and practice, without com-
promising their neutrality and commitment to strict empiricism
(Cairney and Oliver, 2017; Smith and Stewart, 2017).
Thus, while much has been learned over the previous decades,
we still do not understand well how the power dynamics of
knowledge production inform evidence use, which forms of
interaction between evidence users and producers are most pro-
ductive, or the impact of evidence use on policy or patient out-
comes. We argue that key dimensions for future enquiry include:
understanding what evidence is and is not produced, who pro-
duces evidence, how evidence is framed, how evidence is incor-
porated into decision-making processes, and how all of these
dimensions may be inﬂuenced by the types of problems policy-
makers and clinicians seek to solve. These are the outstanding
questions for the ﬁeld.
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Notes
1 www.nihc/clahrcs.ac.uk, https://www.zonmw.nl/en/.
2 http://www.jla.nihr.ac.uk/about-the-james-lind-alliance/.
3 We note that there is a large and complex literature on evidence use (for example,
Weiss, 1979; Nutley et al., 2007; Parkhurst and Abeysinghe, 2016), discusses what use
‘might’ be. This is of course fundamental to consider before addressing questions
about what should be used, and how to ‘maximise’ it. However, we think this question
is too complex to be properly addressed in the scope of this paper.
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